Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III JR-141 Study in Hunter Syndrome (MPS II)
2020-003200-14Phase 3Active
- Sponsor
- JCR Pharmaceuticals
- Start
- Jun 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pabinafusp alfa in mucopolysaccharidosis type 2, sponsored by JCR Pharmaceuticals. Primary endpoint: Primary endpoint: Change in CSF heparan sulfate level. Started Jun 2021; status: active.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2020-003200-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003200-14.